期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

晚期肾癌免疫治疗新进展 被引量：2

New progress of immunotherapies for advanced renal cell cancer
原文传递
导出
摘要 肾细胞癌(RCC)是泌尿系统常见的恶性肿瘤,早期可行手术根治性切除,晚期对放化疗均不敏感。随着肿瘤生物治疗的研究,晚期RCC的免疫治疗取得了许多实质性的进展。本文综述近年晚期RCC免疫治疗的临床研究进展。 Renal cell cancer （RCC）is the common malignant in urology. For early stage, the main treatment is radical nephrectomy. However, RCC is insensitive to chemotherapy and radiotherapy in late stage. Major progresses in the treatment of metastatic RCC patients have been made through biological treatment of tumor. This review summarizes recent progress in the clinical research on immune treatment of advanced RCC.
作者 王伟 张杰
机构地区 武汉大学人民医院泌尿外科 湖北理工学院附属黄石中心医院
出处 《世界临床药物》 CAS 2014年第2期65-68,共4页 World Clinical Drug
关键词 肾细胞癌(RCC) 免疫治疗 靶向治疗 疫苗 renal cell cancer （RCC） immunotherapy targeted therapy vaccine
分类号 R730.51 [医药卫生—肿瘤] R737.11 [医药卫生—肿瘤]
  • 相关文献

参考文献31

  • 1Gupta K, Miller JD, Li JZ, et al. Epidemiologic andsocioeconomic burden of metastatic renal cell carcinoma(mRCC): a literature review [J]. Cancer Treat Rev, 2008,34(3): 193-205.
  • 2Hutson TE. Targeted therapies for the treatment of metastaticrenal cell carcinoma: clinical evidence [J]. Oncologist, 2011,16 (Suppl 2):S14-S22.
  • 3McDermott DF. Immunotherapy of metastatic renal cellcarcinoma [J]. Cancer, 2009, 115 (10 Suppl): S2298-S2305.
  • 4Wierecky J, Muller MR, Wirths S, et al. Immunologic andclinical responses after vaccinations with peptide-pulseddendritic cells in metastatic renal cancer patients [J]. CancerRes, 2006, 66(11): 5910-5918.
  • 5Amato RJ, Shingler W, Naylor S, et al. Vaccination of renalcell cancer patients with modified vaccinia ankara deliveringtumor antigen 5T4 (TroVax) administered with interleukin2: a phase II trial [J]. Clin Cancer Res, 2008,14 (22):7504-7510.
  • 6Anon. Therapeutics presents new phase 2 data showing itsarcelis. immunotherapy AGS-003 in combination withsunitinib improves progression-free survival (PFS) inpatients with advanced renal cell carcinoma (RCC) [C].[2011-06-05]. http:..www.prnewswire.com.news-releases.argos-therapeutics-presents-new-phase-2-data-showing-its-arcelis-immunotherapy-ags-003-in-combination-with-sunitinib-improves-progression-free-survival-pfs-in-patients-with-advanced-renal-cell-carcinoma-rcc-123189233.html.
  • 7Figlin RA, Nicollete CA,Amin A, et al. Monitoring T-cellresponses in a phase II study of AGS-003, an autologousdendritic cell-based therapy in patients with newly diagnosedadvanced stage renal cell carcinoma in combination withsunitinib [C]. J Clin Oncol, 2011, 29: (15Suppl): Abstract2532. http:..meeting.ascopubs.org.cgi.content.short.29.15_suppl.2532.rss= 1.
  • 8Reinhardt C,Zdrojowy R,Szczylik C, et al. Results ofa randomized phase II study investigating multipeptidevaccination with IMA901 in advanced renal cell carcinoma(RCC) [C]. J Clin Oncol, 2010, 28 (15S): Abstract 4529.http:..meeting.ascopubs.org.cgi.content.abstract.28.15_suppl.4529.
  • 9Bukowski RM, Sharfman W, Murthy S, et al Clinical resultsand characterization of tumor-infiltrating lymphocytes with orwithout recombinant interleukin 2 in human metastatic renalcell carcinoma [J]. Cancer Res, 1991, 51 (16): 4199-4205.
  • 10Harrop R, Shingler WH, McDonald M, et al. MVA-5T4-induced immune responses are an early marker of efficacy inrenal cancer patients [J]. Cancer Immunol Immunother, 2011,60(6): 829-837.

同被引文献16

引证文献2

二级引证文献3

世界临床药物
2014年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部